The herpes simplex virus (HSV) recombinant virus R7020 is
Introduction
Viral oncolysis is based on targeting tumor cells for destruction with viruses designed to preferentially attack cancer cells. An ideal virus should exhibit minimal pathogenic manifestations in a host debilitated by progression of cancer. Attenuated replication-competent viruses have potential as antitumor agents. The reason for this therapeutic potential is that these viruses need not initially infect every tumor cell to be effective oncolytic agents. In recent years, replication conditional herpes simplex virus-1 (HSV-1), adenovirus, and reovirus have been tested for antitumor efficacy. [1] [2] [3] Attenuated HSV-1 was initially proposed for the treatment of gliomas. 1, [4] [5] [6] [7] The most common current attenuated HSV-1 virus (G207) used in antitumor studies is deleted of two viral genes; the large subunit of viral ribonucleotide reductase (ICP6) and both copies of the ␥ 1 34.5. 5, 8, 9 G207 has shown antitumor efficacy against a wide variety of non-CNS histo-
ential results in antitumor efficacy between the two cell lines in tumor xenografts. Ionizing radiation enhanced the replication of R7020 in Hep3B xenografts. Moreover, the combination of ionizing radiation and virus caused a greater regression of xenograft volume than either R7020 or radiation alone. Ionizing radiation had no effect on the replication of R7020 virus in Huh7 xenografts. These results indicate that a regimen involving infection with an appropriate herpesvirus such as R7020 in combination with ionizing radiation can be highly effective in eradicating certain tumor xenografts.
Gene Therapy (2002) 9, 75-80. DOI: 10.1038/sj/gt/3301620 logical tumors. [10] [11] [12] [13] Here, we describe experimental studies with a recombinant herpes simplex virus (R7020) that is non-pathogenic in human studies and yet is highly destructive to specific tumors in mice.
R7020 is a genetically engineered virus initially engineered as a candidate for prophylactic immunization against HSV-1 and HSV-2 infection.
14,15 The HSV-1 backbone was deleted of a 14.5 kbp region spanning a region 3Ј of the ICP27 gene through the internal inverted long repeat of the viral DNA genome and a portion of the coding sequences of the U L 23 encoding viral thymidine kinase and U L 24. The genes deleted in R7020 include U L 55, U L 56 and the internal repeat copy (one copy) of ␣0, ␥ 1 34.5, ORF O and ORF P.
14 In place of the large deletion, R7020 carries the HSV-1 thymidine kinase gene under an ␣ promoter and a fragment derived from the HSV-2 genome encoding HSV-2 glycoproteins G, D, I and a portion of E. The virus was extensively tested for genetic stability and for virulence in mice, guinea pigs, rabbits and nonhuman primates.
14,15 R7020 was tested as a candidate antitumor agent for non-CNS tumors; head and neck epithelial squamous cell carcinoma and prostate adenocarcinoma xenografts in athymic nude mice.
16 R7020 (termed NV1020) has also recently been reported to retain its antitumor efficacy in animal tumor models that have been immunized before viral oncolytic treatment and in bladder tumor models. 17, 18 Previously, ionizing radiation was shown to increase the lytic activity of the HSV-1. 19 Specifically, experiments with a genetically engineered HSV-1 (␥ 1 34.5 -/-, R3616) resulted in viral dispersion to greater distances from the site of inoculation in the tumor and viral titers that were higher in irradiated tumors than in tumors receiving virus alone. Mice carrying human glioma xenografts in both flanks and orthotopic nude mouse models exposed to both virus and ionizing radiation also exhibited greater xenograft regression and survival than mice treated with either radiation or virus alone. 19, 20 The hypothesis currently under study is that radiation induces a stress/repair response in tumor cells that enables more effective viral replication. The advantage of ionizing radiation is the ability to target spatially and temporally a tumor mass to receive a specific dose. Thus, ionizing radiation provides an opportunity to enhance the replicative capability of attenuated viruses by specifically creating a conducive environment within the irradiated tumor in contrast to the non-irradiated surrounding normal tissue.
In this article we report the effects of R7020 and ionizing radiation in hepatoma tumor models. The results indicated that (1) R7020 replicated and lysed Hep3B hepatoma cells to a greater extent than Huh7 hepatoma cells in tissue culture; (2) the relative in vitro sensitivity of Hep3B cells to R7020 translated to Hep3B tumor xenograft volume regression whereas Huh7 xenografts exhibited a modest delay in tumor growth volume when R7020 injected xenografts were compared with buffer injected xenograft controls; (3) R7020 replicated to higher titers in irradiated Hep3B xenografts compared with nonirradiated xenografts which correlated with enhanced Hep3B tumor xenograft volumetric reduction.
Results

Replication of R7020 in hepatoma cell line in cell culture
To determine the replicative ability of R7020 in hepatomas, two human hepatoma cell lines were studied: Hep3B and Huh7. R7020 replication was characterized by measuring virus production and cell viability. To determine whether R7020 can replicate in Hep3B and Huh7, cells were infected at a multiplicity of infection (MOI) of 1. Eighteen hours after infection, cells were harvested and viral titers were quantified ( Figure 1 ). Thirty-five-fold more virus was recovered in Hep3B cells compared with Huh7 cells (P Ͻ 0.001). Cell viability was also assessed 
Hepatoma xenograft sensitivity to R7020
To determine the efficacy of R7020 as an oncolytic agent for established tumor xenografts, human hepatoma xenografts were grown in the hind limb of athymic nude mice and then intratumorally inoculated with R7020. Hepatoma xenografts were grown and injected with a single dose of 2 × 10 7 p.f.u. R7020 or buffer on day 0. Control Hep3B and Huh7 xenografts injected with buffer on day 0 continued to grow over the course of the experiment (Figure 3a and b). Hep3B xenografts injected with R7020 experienced significant reduction in tumor volume compared with controls. At 18 days after infection, Hep3B xenografts had an eight-fold decrease in average fractional tumor volume compared with control xenografts (P Ͻ 0.001). One of the three Hep3B xenografts completely regressed with no palpable tumor by day 18. In contrast, Huh7 xenografts demonstrated less sensitivity to the antitumor effects of R7020 with a delay in tumor growth. At 18 days after infection, Huh7 xenografts had a 1.6-fold decrease in average fractional tumor volume compared with buffer injected xenografts (P = 0.053).
Interaction of R7020 with ionizing radiation in hepatoma xenografts
We next studied the effects of combining ionizing radiation with R7020. To ascertain if ionizing radiation would result in increased R7020 replication in hepatoma xenografts, Hep3B and Huh7 xenografts were grown in the flank of athymic nude mice and infected with 2 × 10 7 p.f.u. R7020 followed by 10 Gy ionizing radiation 6 h after infection on day 0. Three xenografts per treatment were excised at days 3, 7 and 14 after infection and viral titers were determined. A 2.6-fold increase in viral titers was seen in irradiated Hep3B xenografts when compared with non-irradiated infected xenografts 7 days after treatment (Figure 4a , P = 0.017). Irradiation of Huh7 xeno- grafts yielded a 1.4-fold increase in viral titers, however, this increase was not statistically significantly (Figure 4b , P = 0.457). At 14 days after infection and irradiation, irradiated Hep3B xenografts still had 2.4-fold more virus than non-irradiated xenografts, however, this difference was not statistically significant (P = 0.118). Also of note in the non-irradiated xenografts, viral replication was more robust in Hep3B compared with Huh7 xenografts (Figure  4a and b) . At 3 days after infection Hep3B non-irradiated xenografts had 3.7-fold greater virus than Huh7 xenografts (P = 0.007), which is consistent with our results above which show Hep3B cells support greater viral replication in vitro and Hep3B xenografts are more responsive in vivo to R7020 as measured by fractional tumor volume response compared with Huh7 cells and xenografts (Figures 1-3) .
The effects of combining R7020 with ionizing radiation on hepatoma xenograft tumor volumes Hepatoma xenografts were grown and randomized to the following treatment groups: control, irradiation alone, R7020 alone or R7020 combined with IR. Mean initial Hep3B tumor volumes for the control, IR, R7020 and IR + Gene Therapy
Figure 4 Kinetics of R7020 replication in non-irradiated and irradiated hepatoma xenografts. 2 × 107 p.f.u. of R7020 were injected intratumorally into Hep3B (a) or Huh7 (b) hepatoma xenografts. Irradiated tumors received 10 Gy 6 h after infection. Xenografts were harvested at 3, 7 and 14 days after infection and assayed for the amount of virus within the tumors. Error bars represent the standard error.
R7020 treatment groups were 368, 364, 364 and 352 mm 3 , respectively. Mean initial Huh7 tumor volumes for the control, IR, R7020 and IR + R7020 treatment groups were 426, 438, 457 and 450 mm 3 , respectively. The overall results are shown in Figure 5 . All untreated xenografts grew progressively, with Huh7 xenografts growing more rapidly than Hep3B xenografts. The tumor volume doubling time for Huh7 was approximately 1.3 days for Huh7 and 5 days for Hep3B xenografts.
The results of Hep3B xenografts are shown in Figure  5a (P Ͻ 0.001, ANOVA of treatment groups). Treatment with IR alone resulted in an average fractional tumor volume of 0.35 at 45 days after initiation of treatment. All tumors then began to regrow. The average fractional tumor volume of xenografts treated with R7020 was 0.32 at day 45. The tumors can be broken down into two subsets to determine if they regrew. Tumors that were Ͻ260 mm 3 at the initiation of treatment showed complete regression up to day 60, while tumors >500 mm 3 regrew starting at day 45. For hepatoma xenografts treated with both R7020 and IR, the average fractional tumor volume was 0.01 at day 45. Seven of eight mice had non-palpable tumors, and the remaining hepatoma xenograft had a fractional tumor volume of 0.06. None of the tumors regrew up to day 60. In the combined treatment group with the xenografts without palpable tumors, two mice had tumors Ͻ200 mm 3 on day 0 and the five remaining mice had initial tumor volumes between 405 and 624 mm 3 . These results indicate that combining IR with R7020 was highly effective in large and small hepatoma xenografts whereas R7020 alone is effective in small hepatoma xenografts. Overall, no tumors treated with IR resulted in complete regression and 50% of tumors treated with R7020 alone while 88% of tumors treated with R7020 and IR showed complete tumor regression.
The results of Huh7 xenografts are shown in Figure  5b (P Ͻ 0.001, ANOVA of the four treatment groups). Irradiation alone resulted in a mean fractional tumor of 2.28 at day 24. Tumors treated with R7020 had a mean fractional tumor volume of 23.45 at which time all mice were killed because of excessive tumor burden per protocol. Tumors receiving both R7020 and IR had an average fractional tumor volume of 0.74 at day 24. No Huh7 xenografts regressed completely in any treatment group. No statistical significance was seen between IR and IR + R7020 treated Huh7 xenografts. Huh7 xenografts treated with R7020 alone exhibited minimal tumor regression, therefore, tumor regression in the IR + R7020 treatment group is attributed to the IR treatment.
Discussion
The two hepatoma cell lines used in this study demonstrated significantly different sensitivities to infection with R7020 in cell culture which directly correlated with tumor xenograft response. R7020 grew to higher titers in Hep3B tumor cells in vitro resulting in significantly reduced cell viability compared with Huh7 cells. The ability of R7020 to grow to higher titers in Hep3B cells than Huh7 cells in tissue culture was reflected in viral yields obtained from infected xenografts of the two cell types. Between 3 and 14 days after infection, Hep3B xenografts had a greater viral titer compared with Huh7 xenografts. These findings directly correlated with the response of xenografts to R7020 treatment as measured by tumor volume regression. Hep3B tumor xenografts had significant reductions in tumor volume when treated with R7020, while Huh7 tumor xenografts exhibited a modest growth delay.
Previously, we showed that ionizing radiation provides a technique to enhance the ability of genetically engineered HSV-1 mutants to replicate in glioblastoma xenografts. 19 In the current study, we demonstrated that ionizing radiation significantly enhanced the ability of R7020 to replicate in Hep3B xenografts up to 14 days after infection and irradiation. The increase in viral yield was approximately 2.5-fold in irradiated Hep3B xenografts compared with non-irradiated xenografts. Increasing the ability of the virus to replicate by ionizing radiation correlated with a more complete hepatoma xenograft response rate. While intratumoral injection of R7020 into Hep3B xenografts was extremely effective for xenografts Ͻ260 mm 3 at the start of the experiment, R7020 alone was not as effective for larger tumor xenografts. Hep3B xenografts treated with ionizing radiation alone also demonstrated effective initial response rates, but regrew. In contrast, none of the Hep3B xenografts treated with both R7020 and ionizing radiation regrew during the duration of the experiment. These results again contend the effectiveness of ionizing radiation in enhancing the ability of R7020 to replicate.
The cell line-specific effects of R7020 raise intriguing questions as to the mechanism of the relative resistance of Huh7 cells and xenografts compared with Hep3B. One major difference in these two hepatoma cell lines was their growth rate in xenografts grown in nude mice. Hep3B xenografts had a longer doubling time compared with Huh7 xenografts. Since tumor volume is the net effect of cell growth versus death, Huh7 xenografts may be growing at a rate that outstrips the rate of viral lysis and spread from the inoculation needle track. However, this possibility seems unlikely. In tissue culture conditions, in which viral delivery is relatively uniform, Huh7 cells did not support the level of viral replication as seen with Hep3B cells. A decreased ability of viral replication may be partially explained by a decrease in the entry of the virus into Huh7 cells. Since recent progress has been made into the cellular receptors responsible for HSV-1 entry into cells, it will be of interest to analyze Hep3B and Huh7 cells for their presence and relative abundance. While IR enhanced R7020 viral recovery from Hep3B xenografts, no such enhancement was seen in infected Huh7 xenografts. These data suggest cell type specificity to enhanced viral replication following ioniz-ing radiation, whose mechanism remains unclear at this point.
The use of genetically engineered HSV as antitumor agents has undergone considerable evolution. The HSV-1 mutant G207 has been extensively studied as an oncolytic agent for gliomas in experimental models and more recently in phase I clinical trials. 21, 22 Additionally, the potential histological types of tumors that may be amenable to genetically engineered HSV-1 has grown dramatically. While these studies have almost exclusively used G207, we have begun to explore the antitumor potential of another multimutated replication competent HSV-1, R7020. R7020 also appears to satisfy the criteria of having both the required safety and desired efficacy of a candidate viral oncolytic agent. Importantly, R7020 grew to higher titers in glioma xenografts compared with R3616, suggesting it may result in more complete tumor eradication. 19 Attenuated HSV-1 may also be compatible with and enhance the therapeutic ratio of conventional cancer therapies. Replication conditional adenovirus and HSV-1 have both been combined with standard chemotherapeutic agents with enhanced tumor regression. [23] [24] [25] For local antitumor therapy, ionizing radiation with gene therapy affords the ability of having more spatial control, potentially limiting toxic side-effects to normal tissue. 26 While we have shown the ability of ionizing radiation to enhance the replicative ability of two genetically engineered HSV-1 as well as increase tumor xenograft regression, it has also been recently reported that ionizing radiation enhanced tumor regression for attenuated replication-competent adenovirus. 16, 19, 20, 27 Thus, the paradigm of utilizing ionizing radiation for cancer gene therapy may also potentially expand to other viral vectors.
Materials and methods
Cells and viruses
Hep3B and Huh7 hepatoma cell lines were a kind gift of Dr Seung-Kew and Jack R Wands (Harvard Medical School, Boston, MA, USA). Vero cells were initially obtained from ATCC (Rockville, MD, USA). Cells were cultured in DMEM supplemented with 10% fetal calf serum and antibiotics. R7020 has been previously described. 14 
R7020 replication in Hep3B and Huh7 cell lines in vitro
Cells were infected at a MOI of 1 with R7020 for 2 h in 199V media at 37°C. After 2 h, the supernatant was aspirated and cells were overlaid with appropriate media and incubated at 37°C. Eighteen hours after infection, triplicate samples were harvested and viral titers were obtained as previously described. 19 Replicative capacity was also assessed by counting the number of viable cells at 24 h after infection utilizing trypan blue exclusion. Statistical analysis was performed using the t test.
R7020 titers in hepatoma xenografts
Hepatoma xenografts were grown in athymic nude mice as previously described. 19 Briefly, 1 × 10 7 Hep3B or Huh7 cells were injected into the right flank of 5-to 6-week-old female, athymic, nude mice (Fredrickson Cancer Research Institute, Bethesda, MD, USA). After 2 weeks tumor xenografts grew to approximately 200 mm 3 and were randomized to treatment groups (R7020 alone or
